McKinsey & Co. will pay $650 million in penalties to the U.S. Department of Justice (DOJ) to settle charges that it advised Purdue Pharma on how to “turbocharge” the sale of Oxycontin in the middle of the U.S. opioid crisis.
McKinsey’s settlement with the DOJ also covered False Claims Act violations related to advising Purdue to submit false and fraudulent claims to federal healthcare programs for medically unnecessary prescriptions of Oxycontin, as well as for failing to disclose conflicts of interest the firm had when it was advising Purdue, and the U.S. Food and Drug Administration, on related matters at the same time.
